Results 181 to 190 of about 2,402,251 (269)

DNA Nanotechnology Meets Peptide and Protein Self‐Assembly

Chemistry – A European Journal, EarlyView.
Combining DNA nanotechnology with peptide and protein assembly provides complementary platforms for the rational engineering of functional biomaterials. This Perspective discusses the emerging field of self‐assembling DNA‐peptide and DNA‐protein hybrid systems that combine the structural precision and programmability of DNA nanotechnology with the ...
Marcel Hanke, Nanjundan Raghul, Adrian Keller, Veikko Linko, Verónica I. Dodero   +4 more
wiley   +1 more source

[Guidelines for iron chelation therapy in thalassemia in China (2025)]. [PDF]

Zhongguo Dang Dai Er Ke Za Zhi
Committee of Thalassemia Prevention and Treatment, China Maternal and Child Health Association, Subspecialty Group of Hematology, Society of Pediatrics, Chinese Medical Association, China Thalassemia Prevention and Control Collaboration Network, Editorial Board of Chinese Journal of Contemporary Pediatrics.   +6 more
europepmc   +1 more source

Green and sustainable synthesis of magnetite from copper slag via citrate complexation for methylene blue dye removal from water

The Canadian Journal of Chemical Engineering, EarlyView.
Abstract This study proposes a novel, green, and sustainable method for synthesizing magnetic iron oxides from metallurgical copper slag (CS), leveraging its iron content as a valuable resource. Iron was extracted via acid leaching using edible citric acid (ECA), forming a citrate–iron complex (CSL), which was subsequently thermally decomposed at 300°C
Melisa Portilla‐Sangabriel, Karen Valencia García, Tania‐Ariadna García‐Mejía, Agileo Hernández‐Gordillo, Rosa‐María Ramírez‐Zamora   +4 more
wiley   +1 more source

Melanin Nanoparticles as a Safe and Effective Iron Chelation Therapy: An ex vivo Assessment of Human Placental Transfer in Pregnant Beta-Thalassemia. [PDF]

Int J Nanomedicine
Bakhamis N, Awoyemi T, Vatish M, Townley H.   +3 more
europepmc   +1 more source

One century of teaching, research, and innovation in chemical engineering in Mexico: The role of chemical engineering in the background and future of polymer science and industrial production in Mexico

The Canadian Journal of Chemical Engineering, EarlyView.
Timeline of key academic milestones and individuals that shaped chemical engineering at FQ‐UNAM and in Mexico. Abstract One hundred years after the beginning of the teaching of Chemical Engineering in Mexico, which started in 1925 in the former National School of Chemical Sciences, currently Faculty of Chemistry (FQ) at National Autonomous University ...
Patricia Pérez‐Salinas, Alberto Rosas‐Aburto, Eduardo Vivaldo‐Lima   +2 more
wiley   +1 more source

Iron Chelation Therapy Elicits Innate Immune Control of Metastatic Ovarian Cancer. [PDF]

Cancer Discov
Sandoval TA, Salvagno C, Chae CS, Awasthi D, Giovanelli P, Marin Falco M, Hwang SM, Teran-Cabanillas E, Suominen L, Yamazaki T, Kuo HH, Moyer JE, Martin ML, Manohar J, Kim K, Sierra MA, Ramos Y, Tan C, Emmanuelli A, Song M, Morales DK, Zamarin D, Frey MK, Cantillo E, Chapman-Davis E, Holcomb K, Mason CE, Galluzzi L, Ni Zhou Z, Vähärautio A, Cloonan SM, Cubillos-Ruiz JR.   +31 more
europepmc   +1 more source

Interface‐Engineered MXene/g‐C3N4 Heterostructures for Energy and Environmental Applications

EcoEnergy, EarlyView.
This review highlights how interface engineering in MXene/g‐C3N4 heterostructures regulates charge transfer, band alignment, and surface chemistry, enabling broad applications in photocatalytic conversion, environmental remediation, energy storage, and multifunctional sensing/therapy. ABSTRACT Two‐dimensional MXene/g‐C3N4 heterostructures have recently
Feng Wang, Geng Liu, Xiaoqiang An
wiley   +1 more source

Combined Topography-Guided Trans-Epithelial PRK and PTK for Treatment of Calcific Band Keratopathy Unresponsive to EDTA Chelation Therapy. [PDF]

Int Med Case Rep J
Passidomo F, Addabbo G, Pignatelli F, Niro A, Buonamassa R.   +4 more
europepmc   +1 more source

Considerations for drug trials in hypertrophic cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1095-1112, April 2025.
Abstract Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter‐defibrillators to prevent sudden cardiac death. The need for disease‐modifying therapies has been recognized for decades.
John P. Farrant, Matthias Schmitt, Anna B. Reid, Clifford J. Garratt, William G. Newman, Aneil Malhotra, Rhys Beynon, Masliza Mahmod, Betty Raman, Robert M. Cooper, Dana Dawson, Thomas Green, Sanjay K. Prasad, Anvesha Singh, Susanna Dodd, Hugh Watkins, Stefan Neubauer, Christopher A. Miller   +17 more
wiley   +1 more source

Targeted chelation therapy decreases NLRP3 expression by vascular cells and acts as senomorphic in chronic kidney disorder induced vascular calcification. [PDF]

Int J Immunopathol Pharmacol
Arora S, Halsey G, Zohora FT, Swiss A, Vyavahare N.   +4 more
europepmc   +1 more source